Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189708052> ?p ?o ?g. }
- W3189708052 endingPage "3924" @default.
- W3189708052 startingPage "3924" @default.
- W3189708052 abstract "Vascular disrupting agents (VDAs), such as DMXAA, effectively destroy tumor blood vessels and cause the formation of large areas of necrosis in the central parts of the tumors. However, the use of VDAs is associated with hypoxia activation and residues of rim cells on the edge of the tumor that are responsible for tumor regrowth. The aim of the study was to combine DMXAA with radiotherapy (brachytherapy) and find the appropriate administration sequence to obtain the maximum synergistic therapeutic effect. We show that the combination in which tumors were irradiated prior to VDAs administration is more effective in murine melanoma growth inhibition than in either of the agents individually or in reverse combination. For the first time, the significance of immune cells’ activation in such a combination is demonstrated. The inhibition of tumor growth is linked to the reduction of tumor blood vessels, the increased infiltration of CD8+ cytotoxic T lymphocytes and NK cells and the polarization of macrophages to the cytotoxic M1 phenotype. The reverse combination of therapeutic agents showed no therapeutic effect and even abolished the effect of DMXAA. The combination of brachytherapy and vascular disrupting agent effectively inhibits the growth of melanoma tumors but requires careful planning of the sequence of administration of the agents." @default.
- W3189708052 created "2021-08-16" @default.
- W3189708052 creator A5019985466 @default.
- W3189708052 creator A5037799909 @default.
- W3189708052 creator A5043007356 @default.
- W3189708052 creator A5050496281 @default.
- W3189708052 creator A5052217204 @default.
- W3189708052 creator A5057030212 @default.
- W3189708052 creator A5076705408 @default.
- W3189708052 creator A5083233367 @default.
- W3189708052 creator A5084587551 @default.
- W3189708052 date "2021-08-04" @default.
- W3189708052 modified "2023-10-03" @default.
- W3189708052 title "The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors" @default.
- W3189708052 cites W1782542250 @default.
- W3189708052 cites W1866003637 @default.
- W3189708052 cites W1898887656 @default.
- W3189708052 cites W1970395106 @default.
- W3189708052 cites W1975089377 @default.
- W3189708052 cites W197509391 @default.
- W3189708052 cites W1994521878 @default.
- W3189708052 cites W2016263096 @default.
- W3189708052 cites W2016861891 @default.
- W3189708052 cites W2017322644 @default.
- W3189708052 cites W2018329937 @default.
- W3189708052 cites W2029852728 @default.
- W3189708052 cites W2031453628 @default.
- W3189708052 cites W2056304545 @default.
- W3189708052 cites W2057910790 @default.
- W3189708052 cites W2059020146 @default.
- W3189708052 cites W2064428124 @default.
- W3189708052 cites W2079265161 @default.
- W3189708052 cites W2088228460 @default.
- W3189708052 cites W2091686839 @default.
- W3189708052 cites W2124257552 @default.
- W3189708052 cites W2126810504 @default.
- W3189708052 cites W2132564070 @default.
- W3189708052 cites W2135664375 @default.
- W3189708052 cites W2152066118 @default.
- W3189708052 cites W2152574565 @default.
- W3189708052 cites W2153173302 @default.
- W3189708052 cites W2161717621 @default.
- W3189708052 cites W2162596729 @default.
- W3189708052 cites W2173816666 @default.
- W3189708052 cites W2174845029 @default.
- W3189708052 cites W2232266376 @default.
- W3189708052 cites W2237126693 @default.
- W3189708052 cites W2239050196 @default.
- W3189708052 cites W2269588674 @default.
- W3189708052 cites W2344746583 @default.
- W3189708052 cites W2404692650 @default.
- W3189708052 cites W2410879014 @default.
- W3189708052 cites W2499593888 @default.
- W3189708052 cites W2516091650 @default.
- W3189708052 cites W2552872119 @default.
- W3189708052 cites W2557682620 @default.
- W3189708052 cites W2599903719 @default.
- W3189708052 cites W2763833914 @default.
- W3189708052 cites W2781426023 @default.
- W3189708052 cites W2782783651 @default.
- W3189708052 cites W2786753426 @default.
- W3189708052 cites W2795875233 @default.
- W3189708052 cites W2807121348 @default.
- W3189708052 cites W2896241146 @default.
- W3189708052 cites W2897257669 @default.
- W3189708052 cites W2905027070 @default.
- W3189708052 cites W2910867684 @default.
- W3189708052 cites W2914098003 @default.
- W3189708052 cites W2914525558 @default.
- W3189708052 cites W2947021030 @default.
- W3189708052 cites W2948093319 @default.
- W3189708052 cites W2955294253 @default.
- W3189708052 cites W2997891042 @default.
- W3189708052 cites W3012307045 @default.
- W3189708052 cites W3037603513 @default.
- W3189708052 cites W3045481378 @default.
- W3189708052 cites W3095599757 @default.
- W3189708052 cites W3097294978 @default.
- W3189708052 cites W3157087909 @default.
- W3189708052 cites W3159942634 @default.
- W3189708052 cites W3161199852 @default.
- W3189708052 cites W3164702212 @default.
- W3189708052 cites W3167533141 @default.
- W3189708052 doi "https://doi.org/10.3390/cancers13163924" @default.
- W3189708052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8394873" @default.
- W3189708052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34439079" @default.
- W3189708052 hasPublicationYear "2021" @default.
- W3189708052 type Work @default.
- W3189708052 sameAs 3189708052 @default.
- W3189708052 citedByCount "8" @default.
- W3189708052 countsByYear W31897080522022 @default.
- W3189708052 countsByYear W31897080522023 @default.
- W3189708052 crossrefType "journal-article" @default.
- W3189708052 hasAuthorship W3189708052A5019985466 @default.
- W3189708052 hasAuthorship W3189708052A5037799909 @default.
- W3189708052 hasAuthorship W3189708052A5043007356 @default.
- W3189708052 hasAuthorship W3189708052A5050496281 @default.
- W3189708052 hasAuthorship W3189708052A5052217204 @default.